基因预测的铁补充药物标和炎性肠病之间的相关性:孟德尔的随机化研究
Dong-Lin Li1, Chuan Jiang2, Zhong-An Guan2
1First School of Clinical Medicine, Shandong Traditional Chinese Medicine University, Jinan, Shandong Province, China.
这项研究使用遗传数据来探索铁补充剂与炎症性肠病 (IBD) 之间的联系. 某些基因,如EGLN1和FEN1,与IBD风险增加有关,这表明潜在的治疗点.
科学领域:
- 遗传学和精准医学 遗传学和精准医学
- 胃肠病学 胃肠病学
- 药物基因组学 药物基因组学
背景情况:
- 炎症性肠病 (IBD),包括性结肠炎 (UC) 和克罗恩病 (CD),对健康造成重大负担.
- 补充铁是常见的,但其对IBD病原体的确切影响尚不清楚.
- 了解遗传倾向和药物点对于开发有效的IBD治疗至关重要.
研究的目的:
- 调查基因代理铁补充剂药物与IBD发展风险之间的因果关系.
- 确定铁补充剂影响的特定基因和途径,可能导致IBD发展.
- 探索新的IBD疗法潜在的遗传标.
主要方法:
- 利用门德尔的随机化 (MR) 分析来评估药物向基因与IBD,UC和CD之间的因果关系.
- 确定了8种常见的铁补充剂药物及其监管目标,并提取了SNP数据用于下游标记物,如血红蛋白.
- 包括欧洲和亚洲人群,进行双向和多变量MR与严格的灵敏度分析.
主要成果:
- 基因代理的Egl9同源1 (EGLN1) 显示与IBD,UC和CD风险增加有关.
- 片内核酶1 (FEN1) 与更高的IBD和CD风险有关.
- 费里丁重链1 (FTH1) 和转激素受体2 (TFR2) 与CD风险增加有关;DNA聚合酶β (POLB) 与CD风险降低有关.
- 在IBD和EGLN1.1之间观察到双向因果关系. 亚洲队列分析显示EGLN1,FEN1,ITGB3和TFRC与UC的关联.
结论:
- 包括EGLN1,FEN1,ITGB3,TFRC,FTH1和POLB在内的特定基因可能与炎症性肠病的发病有关.
- 对铁代谢和相关途径的遗传洞察力可能为IBD提供新的治疗策略.
- 需要进一步的研究来验证这些发现并探索临床应用.
更多相关视频
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
09:04DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
